Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018
Crossref DOI link: https://doi.org/10.1007/s40121-018-0220-3
Published Online: 2018-11-08
Published Print: 2018-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
McGirr, Ashleigh http://orcid.org/0000-0002-5570-8837
Iqbal, Shehzad M.
Olbrecht, Jan
Varghese, Lijoy
Funding for this research was provided by:
GlaxoSmithKline
Text and Data Mining valid from 2018-11-08
Version of Record valid from 2018-11-08
Article History
Received: 21 August 2018
First Online: 8 November 2018